Arvinas Lands First FDA-Approved PROTAC Drug, Licenses to Rigel
Event summary
- Arvinas received FDA approval for VEPPANU (vepdegestrant), the first PROTAC therapy, for ESR1-mutated advanced breast cancer.
- Licensed global rights for VEPPANU to Rigel Pharmaceuticals, pending regulatory approvals.
- Reported $614.9M in cash and marketable securities as of March 31, 2026, down from $685.4M at year-end 2025.
- Presented Phase 1 data for ARV-102 showing biomarker reductions in Parkinson’s patients.
- Initiated Phase 1 trial for ARV-027 in healthy volunteers, with single-ascending dose data expected in 2H26.
The big picture
Arvinas’ FDA approval for VEPPANU marks a milestone in the PROTAC drug modality, positioning the company as a pioneer in targeted protein degradation. The licensing deal with Rigel Pharmaceuticals could expand VEPPANU’s market reach, while the company’s diverse pipeline targets high-unmet-need indications in neurodegenerative diseases and oncology. The strategic shift in leadership and financial discipline suggests a focus on long-term sustainability amid a competitive biotech landscape.
What we're watching
- Pipeline Execution
- Whether Arvinas can sustain momentum with its diverse pipeline, including ARV-102 for Parkinson’s and ARV-6723 for immuno-oncology.
- Commercialization Strategy
- How Rigel Pharmaceuticals will execute the global commercialization of VEPPANU and its impact on Arvinas’ revenue streams.
- Financial Sustainability
- The pace at which Arvinas burns through its cash reserves, given the $70.5M decrease in Q1 2026.
Related topics